Investigation of interindividual factors in erlotinib and its metabolites pharmacokinetics, clinical responses and adverse reactions in Japanese non-small cell lung cancer patients receiving oral erlotinib.
Not Applicable
Recruiting
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-UMIN000013388
- Lead Sponsor
- Department of Hospital Pharmacy Hamamatsu University School of Medicime
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients discontinued receiving treatment of oral erlotinib 2. Patients having severe kidney dysfunction or liver dysfunction 3. Patients who are judged by physicians as inappropriate for study enrollment
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Trough plasma concentrations of erlotinib and OSI-420 before dosing on day 8 or later
- Secondary Outcome Measures
Name Time Method